NEW YORK, April 26, 2017 /PRNewswire/ --
Stock-Callers.com revisits the Medical Appliances and Equipment industry, which includes companies that are engaged in the manufacture of medical instruments such as dental and surgical appliances. For assessment today are: Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Medtronic PLC (NYSE: MDT), and EnteroMedics Inc. (NASDAQ: ETRM). Learn more about these stocks by downloading their comprehensive and free reports at:
On Tuesday, shares in Abbott Park, Illinois headquartered Abbott Laboratories saw a slight decline of 0.84%, ending the day at $43.76. The stock recorded a trading volume of 6.78 million shares. The Company's shares have advanced 9.22% over the previous three months and 15.37% since the start of this year. The stock is trading above its 200-day moving average by 5.28%. Moreover, shares of Abbott Labs, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 47.17.
On April 14th, 2017, Abbott Labs and Alere Inc. announced that they have agreed to amend the existing terms of their agreement for Abbott's acquisition of Alere. Under the amended terms, Abbott will pay $51 per common share to acquire Alere for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion.
On April 20th, 2017, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $50 a share to $52 a share. ABT complete research report is just a click away and free at:
Shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. ended the day 0.70% higher at $25.74. A total volume of 10.26 million shares was traded, which was above their three months average volume of 7.88 million shares. In the last month and the previous three months, the stock has gained 5.84% and 9.35%, respectively. Additionally, the Company's shares have advanced 19.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.06% and 9.87%, respectively. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 68.29.
On April 18th, 2017, Boston Scientific has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator System, who are aged 65 and older, with a history of prior heart attack, diabetes, and moderately reduced left ventricular ejection fraction. This subset of patients is at increased risk for sudden cardiac arrest, but not currently considered guideline-appropriate candidates for implantable cardiac defibrillators. The complimentary report on BSX can be downloaded at:
At the close of trading on Tuesday, shares in Dublin, Ireland headquartered Medtronic PLC finished 1.38% higher at $81.76 with a total trading volume of 4.24 million shares. The stock has advanced 0.94% in the last one month, 11.33% over the previous three months, and 15.39% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 1.63% and 1.61%, respectively. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 62.39.
On April 24th, 2017, Medtronic launched its new StealthStation™ technology at the American Academy of Neurological Surgeons annual conference in Los Angeles. StealthStation technology has been a mainstay in neurosurgery suites for the past 25 years, being used in more than 2.25 million procedures. With the new StealthStation™ S8 model, the Company brings an advanced solution to neurosurgeons with enhanced workflows, efficiencies, and more comprehensive data integration, providing useful surgical navigation information. Sign up for your complimentary research report on MDT at:
St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares recorded a trading volume of 375,050 shares at the end of yesterday's session. The stock closed the day 9.59% lower at $4.15. The Company's shares have advanced 107.50% on an YTD basis. The stock is trading above its 200-day moving average by 46.95%. Additionally, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 16.23.
On April 24th, 2017, EnteroMedics announced that it has been named a 2017 Bronze Edison Award Winner by the internationally renowned Edison Awards™ in the Health and Wellness category for its vBloc®Neurometabolic Therapy for the treatment of obesity. The Edison Awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy. Award winners were announced April 20th, 2017 at the Edison Awards Annual Gala in New York City. Get free access to your research report on ETRM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA